BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu S, Hong Y, Chen H, Wu L, Sun F, Wang J, Zhu J, Que Y, Zhang L, Zhen Z, Sun X, Huang J, Zhang Y. The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors. Front Pharmacol 2022;13:711704. [DOI: 10.3389/fphar.2022.711704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 . Catequentinib. Reactions Weekly 2022;1911:125-125. [DOI: 10.1007/s40278-022-17422-8] [Reference Citation Analysis]